NICE recommends Epclusa (sofosbuvir/velpatasvir) as a treatment option for six genotypes of HCV.- Gilead Sciences
The National Institute for Health and Care Excellence (NICE)has recommended Epclusa (sofosbuvir/velpatasvir) from Gilead Sciences as a treatment option for all six genotypes of HCV, with the condition that it is not recommended for treatment-naïve, non-cirrhotic genotype 2 patients who are able tolerate interferon-based therapy. In that one specific setting, interferon-inclusive regimens are viewed more cost-effective than Epclusa.
NICE recognized a need for HCV therapy with fewer adverse side effects and for patients with genotype 3 of the virus, who comprise about 44% of the patient base. Gilead and NICE have agreed to a confidential discount to the NHS for Epclusa.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.